The Fund will seek to achieve an above average rate of income combined with sound prospects for capital growth.
Name | % Net Assets |
---|---|
GlaxoSmithKline PLC | 6.4% |
Royal Dutch Shell PLC | 6.1% |
AstraZeneca PLC | 5.9% |
British American Tobacco PLC | 5.4% |
BT Group PLC | 5.3% |
Unilever PLC | 3.9% |
Imperial Tobacco Group PLC | 3.3% |
Scottish & Southern Energy PLC | 3.1% |
Compass Group PLC | 3.0% |
BG Group PLC | 2.5% |
Key | % Net Assets |
---|---|
GlaxoSmithKline PLC | 6.4% |
Royal Dutch Shell PLC | 6.1% |
AstraZeneca PLC | 5.9% |
British American Tobacco PLC | 5.4% |
Other | 76.2% |
Date | 21-Nov-2024 |
---|---|
NAV | 104.37p |
Currency | GBP |
Change | -0.070p |
% | -0.07% |
YTD change | 4.13p |
YTD % | 4.12% |
Fund Inception | 30/09/1985 |
---|---|
Fund Manager | Leigh Harrison |
TER | 1.61 (30-Mar-2012) |
Minimum Investment | |
---|---|
Initial | £2000 |
Additional | n/a |
Savings | n/a |
Charges | |
---|---|
Initial | 3.75% |
Annual Mang't | 1.50% |
Exit | n/a |
Name | % |
---|---|
Standard deviation | 0.02 |
Sharpe ratio | 0.08 |
You are here: research